Evidence map›Paper›PMID 31145831›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2019

Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's disease.

John D Heiss, Codrin Lungu, Dima A Hammoud, Peter Herscovitch, Debra J Ehrlich, Davis P Argersinger, Sanhita Sinharay, Gretchen Scott, Tianxia Wu, Howard J Federoff and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 1 synthesis or guideline pooled it, 118 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. A Phase 1 Study of Convection-Enhanced Delivery of Intraputaminal AAV2-GDNF in Advanced Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026
    Article
  6. Article
  7. Clinical GDNF delivery methods for Parkinson's disease.Journal of Parkinson's disease · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Recent developments in translational imaging of in vivo gene therapy outcomes.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

John D HeissSurgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
Codrin LunguDivision of Clinical Research, and Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
Dima A HammoudRadiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Peter HerscovitchPositron Emission Tomography Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Debra J EhrlichParkinson's Disease Clinic, Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
Davis P ArgersingerSurgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
Sanhita SinharayRadiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Gretchen ScottSurgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
Tianxia WuClinical Trials Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
Howard J FederoffDepartment of Neurology, University of California-Irvine, Irvine, California, USA.
Kareem A ZaghloulSurgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
Mark HallettHuman Motor Control Section, Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-3180-6811
Russell R LonserDepartment of Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Krystof S BankiewiczDepartment of Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
National Institutes of Health · USNational Institutes of Health Clinical Center · USThe Ohio State University Wexner Medical Center · USUniversity of California, Irvine · USUniversity of California, San Francisco · US

Funding

Investigating the neural mechanisms of human cognitive function through intracranial recordingsZIANS003144 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI ZAGHLOUL, KAREEM · 2014 to 2025
$36.1M
Central Nervous System Drug Delivery TechniquesZIANS003051 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI HEISS, JOHN · 2009 to 2025
$9.8M
Therapy of Movement DisordersZIANS003032 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI HALLETT, MARK · 2009 to 2023
$3.7M
Intramural NIH HHS Z99 NS999999
6 · The paper itself

Abstract

objectiveTo investigate the safety and tolerability of convection-enhanced delivery of an adeno-associated virus, serotype-2 vector carrying glial cell line-derived neurotrophic factor into the bilateral putamina of PD patients.

methodsThirteen adult patients with advanced PD underwent adeno-associated virus, serotype-2 vector carrying glial cell line-derived neurotrophic factor and gadoteridol (surrogate MRI tracer) coinfusion (450 μL/hemisphere) at escalating doses: 9 × 10

resultsAdeno-associated virus, serotype-2 vector carrying glial cell line-derived neurotrophic factor was tolerated without clinical or radiographic toxicity. Average putaminal coverage was 26%. UPDRS scores remained stable. Ten of thirteen and 12 of 13 patients had increased [

conclusionAdeno-associated virus, serotype-2 vector carrying glial cell line-derived neurotrophic factor infusion was safe and well tolerated. Increased [

Indexed as

Genetic TherapyAdultDependovirusFemaleHumansMagnetic Resonance ImagingMaleParkinson DiseaseParkinsonian DisordersPutamenconvection-enhanced deliveryGDNFgene therapyParkinson'svector

Identifiers

PMID31145831
PMCPMC6642028
OpenAlexW2947416925

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.